That is necessary, since the way a protein in the human body folds figures out if a pharmaceutical will be able to bind to that protein and be efficient. Simply put, we have to know how these proteins fold if we desire a drug to work. Historically, this has actually been a trial-and-error procedure (jeff brown investor prediction). Now, Alpha, Fold can anticipate protein folding with 92. 4% accuracy. That's going to make it a lot easier to create drugs that do what they're designed to do. This was a development almost nobody discovered. But it's going to have extensive ramifications for treating disease. I predict that Alpha, Fold will be 98% precise by the end of 2021.
And, naturally, there will be plenty of financial investment chances in this space, too. Shifting subjects It's going to be an excellent year for bitcoin. I'm bullish on it in 2021 (future report). That stated, I still think bitcoin will continue to be unstable. We're close to all-time highs. I wouldn't be shocked if it drew back perhaps substantially before going higher - diplomatic relations. I have actually been covering bitcoin for a long time now. One of the first research study reports I ever published was on bitcoin. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that initial suggestion, I entitled my report "What's the Big Offer With Bitcoin?" That shows you where the conversation was at the time. We were mostly informing readers. However that's not the huge question any longer. Now we're seeing institutional money finally take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, niche enterprise. Mass, Mutual is a trusted 170-year-old institution. So consider that. In 5 years, we went from educating readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
Which's a big factor I'm bullish on it this year. second wave. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus offer forecast 2020 was a record year for IPOs. 552 U.S. business went public the most in more than twenty years. These business raised a total of $172 billion. That's an all-time high beating the previous yearly record by 43%. I forecast 2021 will be another record year in IPOs. There are a lot of fantastic private business on the verge of hitting the general public markets And I've been working on a brand-new method for you to invest even prior to these business go public.
This opportunity has been constructing over the last few years. I can't wait to inform you all about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to discover all the information. Go right here to schedule your spot totally free.
Emma Walsh here, managing editor of the Journal. Regular Journal readers know that tech isn't our usual beat (jeff brown biotech pick). And when it concerns tech investing, we leave it to the specialists. Thankfully, we have several such professionals in our Rolodex. Our coworker Jeff Brown will recognize to our long time readers. He is among the most accomplished tech investing professionals we understand (jeff brown biotech stocks). In fact, he had a number of triple-digit returns in his Brownstone Research study portfolios in 2015. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to have a look at the big photo and forecast what's just around the corner.
That consists of things like 5G networks, biotech, expert system, and much more. These patterns are experiencing rapid development and producing extraordinary opportunities for financiers. I want to ensure all our readers are gotten ready for what's next. And with that in mind, let me draw the picture of what I see can be found in the next 12 months Our new 5G (fifth-generation) wireless networks are a topic I have actually been covering for years now. jeff brown genetic sequencing stock. However despite what numerous readers may believe, this is a pattern that's just getting started. Despite the fact that the COVID-19 pandemic disrupted supply chains in 2015, a remarkable 250 million 5G-enabled devices were still offered.
And all of this eventually resulted in Apple delaying the release of the 5G-enabled i, Phone 12 by 2 months (black sea). Losing 2 months of manufacturing and sales actually impacts how lots of 5G devices are sold in the fiscal year. When you think about all of that, offering 250 million systems is amazing. More notably, the hold-ups caused by the pandemic created a lots of suppressed demand. Which demand is now going to be pushed into 2021. In reality, I predict that more than 500 million 5G devices will be delivered in 2021 - jeff brown genome sequencing. Which's not my only 5G forecast When I have actually talked about 5G in the past, I've explained its three various phases.
In Phase 2, 5G devices go on sale. 5G phones and other products start to reach consumers. And in Phase 3, 5G services start to be offered (tech predictions). That's when we begin to see applications working on 5G networks. Consider things like enormous multiplayer video games over a cellphone. That's not possible with 4G. It will be with 5G. And my 2nd 5G prediction for 2021 is that we will start Phase Three by this summer. This starts something of a virtuous cycle: A lot of people don't actually care about the innovation. But they will care if there are interesting applications that can just be accessed with a 5G phone.
That leads to more 5G apps being established. In reality, 5G is going to open a suite of unbelievable applications: self-driving automobiles, the Web of Things, robotic surgical treatment, and more. All of these innovations need 5G. The financial investment chances going forward will be enormous. Stepping far from 5G, the next crucial technology I anticipate in 2021 is CRISPR hereditary modifying. CRISPR represents "clustered regularly interspaced short palindromic repeat." It's a mouthful. But it's one of the most interesting advancements in biotechnology. At a high level, CRISPR is an innovation that can modify our hereditary makeup as if it were software application.
The program can crash or not work correctly. CRISPR utilizes a similar concept but with our genetic code. "Typos" in our genome can lead to disease. CRISPR can correct these "typos." For many years, CRISPR was mainly a specific niche technology that wasn't well understood. And during that time, there were really just 3 business running in this area. But things are altering. CRISPR is no longer just theoretical. We're seeing real outcomes. We're treating diseases and seeing that this innovation just works. And as an outcome, a "2nd crop" of early-stage CRISPR companies is going public and delivering amazing returns. This entire industry is efficiently a greenfield opportunity.
There's space for lots of companies to exist in this area. the legacy report prediction. And there will be more. That's my forecast for CRISPR in 2021. I forecast that 2 or three more hereditary modifying business will hold their IPOs. Sticking to biotechnology, we are seeing incredible things taking place at the merging of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, just revealed at the end of 2020 that its most current Alpha, Fold software can properly anticipate the folding of a protein based solely on its amino acid sequence with 92. 4% precision. That is essential since the way a protein in the human body folds determines if a pharmaceutical will have the ability to bind to that protein and be effective.
Historically, this has been an experimental procedure. And now, Alpha, Fold can anticipate protein folding with 92. 4% precision. That's going to make it much easier to create drugs that do what they're created to do. And here's my next forecast. I anticipate that Alpha, Fold will be 98% precise by the end of 2021. And we will see not simply one however numerous drug therapies produced using this technology. This was among those breakthroughs that nearly nobody saw. But it's going to have extensive ramifications for treating disease. And, obviously, there will be plenty of financial investment opportunities in this space, too.
It's going to be a great year for bitcoin. I'm bullish on it in 2021. That stated, I still think bitcoin will continue to be unstable. We're close to all-time highs. I would not be shocked if it drew back possibly substantially before going greater. I have actually been covering bitcoin for a long period of time now. One of the very first research study reports I ever released was on bitcoin - democratic republic. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ roi for anyone who followed my suggestion. But at the time of that initial recommendation, I entitled my report, "What's the Big Deal With Bitcoin?" That reveals you where the conversation was at the time.
However nobody is asking that concern anymore. Now, we're seeing institutional money finally taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, niche business. biotech stocks. Mass, Mutual is a 150-year-old organization. So think of that. In five years, we went from educating readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a big factor why I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more bonus offer forecast In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown is worth about $27. 5 million and declares the details is up to date since February 2021, but we might not separately verify this claim. Given Jeff Brown's past, he likely has a substantial net worth, however we can't hammer down an exact figure at this moment. Brown is best known for his sage-like capability to select winning technology stocks. He invested more than 25 years researching innovation companies like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's substantial experience offers him an exceptional viewpoint on the market. He's constantly on the hunt for new opportunities, and he shares numerous of his finest choices in the Near Future Report.
That's full marks, but it's not ridiculously reasoned. Brown has an outstanding reputation as a stock-picker, and he successfully anticipated some of the most significant financial occasions of the past twenty years. Although he does not appear to release his choices to the public, the service's success is a direct indication of Brown's stock-picking prowess. No one on Wall Street gets it ideal every time, however Jeff Brown's precise predictions have made him legions of dedicated fans. That says a lot about his capability. The Future Report is published by Brownstone Research, a prominent financial research publisher. Brownstone Research uses a number of research services with a variety of specializations - biotech stocks.
The business is likewise associated with Bonner & Partners, another well-respected research study publisher - jeff brown investor prediction. On its website, Brownstone says its objective is to offer retail financiers with professional-grade research: "For too long, the very best financial investment research has actually not been available to individual financiers. It has been typically reserved for investment banks, hedge funds, private equity, and high-net-worth clients. jeff brown biotech stock pick for 2020. The mission of Brownstone Research study is to make that kind of exclusive research readily available to any investors aiming to get an edge in the marketplaces. The objective is simple to provide distinct and successful financial investment research found nowhere else." -Brownstone Research study website excerpt from the Jeff Brown is the founder of Brownstone Research, and he also serves as the company's Chief Investment Analyst.
With Brown guiding the ship, Brownstone Research study is a powerhouse publisher with lots to offer its customers. After decades of stable success at the helm of top-tier business like Tesla and Area, X, Elon Musk is a family name throughout most of America. If you know even a bit about the marketplace, you know that he has a reputation as a King Midas of sorts. jeff brown. Whatever he touches turns to gold! Jeff is well aware of Elon Musk's executive prowess, so he always has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next huge project.
In fact, Brown thinks S.A.V. jeff brown biotech genome sequencing. might be "the most significant trend of the 2020s, and he's not alone. Inspect out these quotes from other well-known S.A.V. bulls: Elon's next big act will be weding 2 cutting-edge technologies: synthetic intelligence and electrical automobiles. Musk hopes the mix will help him develop the very first fully-autonomous, self-driving vehicles ever. It's absolutely nothing except the automobile industry's Holy Grail. As you understand, electric vehicles and self-driving automobile stocks have actually been huge this year, but the Wall Street machine has actually been huge on hype without much tangible outcome. Despite a drastic increase in competitors over the previous couple of years, Brown still believes Musk has the very best possibility of putting everything together.
tech could be the magic string that connects everything together. S.A.V. represents Shared Autonomous Car, and it might be the future of transport. Generally, this technology would permit you to rent your automobile as an autonomous, self-driving taxi when you're not using it. You just get out of the automobile and press a button on an app that informs the vehicle to "join the fleet." Next thing you understand, you're unwinding on your couch while your cars and truck shuttles ride-sharers around town. Best of all, you get to keep a large portion of the profits. It sounds outrageous, but it could be closed than you believe.